Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Advertise
  • SUBSCRIBE

DOR BioPharma And Cambrex Enter Into A Process Agreement

By Pharmaceutical Processing | January 20, 2005

DOR BioPharma, Inc. and a subsidiary of Cambrex Corporation have entered into an agreement with respect to process development for potential large scale production of DOR’s proprietary ricin vaccine, RiVax. Under the agreement, Cambrex will provide process development and cGMP production services for RiVax

Ricin toxin is a potential bioterror threat due to its highly lethal toxicity in small doses, ease of manufacture, and ability to be aerosolized. The need for protective countermeasures against ricin has been emphasized by its recent and continued use as a biological weapon.

“We believe RiVax could be an integral part of the U.S. Government’s biodefense arsenal,” stated Gregory J. Davenport, Ph.D., President of DOR’s Biodefense Division. “Cambrex has significant cGMP capacity and a proven track record of manufacturing other developmental vaccines. We are pleased to be working with Cambrex as we endeavor to meet all the requirements for potential procurement by the U.S. Government.”

DOR will work with Cambrex pursuant to DOR’s recently awarded $5.2 million National Institutes of Health (NIH) ricin vaccine development grant. The specific milestones for the RiVax development program funded under the grant to be undertaken by Cambrex include development of a robust process for production and purification of the vaccine. Under the current agreement, Cambrex will be developing the manufacturing process to enable large scale production to produce quantities sufficient for additional clinical testing, fulfillment of all FDA requirements for licensure and, approved, commercial production.

“If these milestones are successfully achieved, DOR will have sufficient vaccine available for future clinical trials, and will be capable of manufacturing RiVax at scale,” commented Alexander P. Haig, Executive Chairman of DOR. “Our goal is to position ourselves as a qualified supplier of ricin vaccine to the U.S. Government. We intend to aggressively pursue all future procurement contracts with the ultimate goal of providing a safe and effective ricin vaccine to our military and at-risk civilians.”

“We are excited to work with DOR on the RiVax project,” commented Gary Mossman, Chief Operating Officer of Cambrex. “We have extensive experience developing production capabilities for vaccines of all types, and we feel privileged to work on this important vaccine that could be a critical component of our national defense.”

In accordance with current FDA guidance, DOR has previously demonstrated the safety and effectiveness of RiVax in multiple relevant animal models. The company has recently announced the initiation of an investigator-sponsored Phase I clinical study to be conducted at the University of Texas, to test the safety and immunogenicity of RiVax in human volunteers using previously produced cGMP material from UT Southwestern. Once these conditions are satisfied, the federal government has the authority under the BioShield Act of 2004 to procure bioterror countermeasures for addition to the Strategic National Stockpile prior to Food and Drug Administration approval.

Related Articles Read More >

This is a photo of the Fujifilm Diosynth Biotechnologies plant under construction in Holly Springs, North Carolina.
Fujifilm, Regeneron ink $3B U.S. manufacturing agreement
This is the logo of Johnson & Johnson.
J&J breaks ground on $2B manufacturing facility in North Carolina
sherwin-williams-pharma-facility (1)
Sherwin-Williams expands flooring solutions for pharma facilities
PHARMAP 2025: Pharma leaders converge in Berlin for fifth anniversary summit
“ppw
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news, technologies, and developments in Pharmaceutical Processing.

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Pharmaceutical Processing World
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index
  • R&D 100 Awards

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Advertise
  • SUBSCRIBE